title: Androstenedione is the preferred androgen source in hormone refractory prostate cancer--response.
authors.affiliation: Department of Surgery, University of Melbourne and Royal Melbourne Hospital, Parkville, Victoria, Australia.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Hovens
authors.affiliation: Department of Surgery, University of Melbourne and Royal Melbourne Hospital, Parkville, Victoria, Australia.
authors.forename: Matthew K H
authors.initials: MK
authors.lastname: Hong
authors.affiliation: Department of Surgery, University of Melbourne and Royal Melbourne Hospital, Parkville, Victoria, Australia. niallmcorcoran@gmail.com.
authors.forename: Niall M
authors.initials: NM
authors.lastname: Corcoran
mesh_terms: D000728:Androgens / Q000378:metabolism*; D000735:Androstenedione / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000378:metabolism*
chemical_list: D000728:Androgens; D000735:Androstenedione